Effects of different types of antihypertensive agents on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials

Journal of Thoracic Disease

Volumn 7, Issue 12, 2015, Pages 2339-2347

  Chen, Xiahuan ^a   Huang, Bo ^a   Liu, Meilin ^a   Li, Xueying ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Antihypertensive agents; Hypertensive; Meta analysis; Vascular stiffness

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CARVEDILOL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; METOPROLOL; NIFEDIPINE; TELMISARTAN; VALSARTAN;

ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; DRUG EFFECT; DRUG EFFICACY; HUMAN; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; SYSTEMATIC REVIEW;

EID: 84954122301     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2015.12.58     Document Type: Article

References (40)

1. Kannel WB. Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J 1999;138:205-10.
2. Kannel WB. Elevated Systolic Blood Pressure as a Cardiovascular Risk Factor. Am J Cardiol 2000;85: 251-5.
3. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-605.
4. Najjar SS, Scuteri A, Shetty V, et al. Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol 2008;51:1377-83.
5. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219.
6. Ichihara A, Kaneshiro Y, Takemitsu T, et al. Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. J Hum Hypertens 2006;20:787-94.
7. Karalliedde J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008;51:1617-23.
8. Takami T, Shigemasa M. Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens Res 2003;26:609-14.
9. Ong KT, Delerme S, Pannier B, et al. Aortic stiffness is reduced beyond blood pressure lowering by shortterm and long-term antihypertensive treatment: a metaanalysis of individual data in 294 patients. J Hypertens 2011;29:1034-42.
10. Protogerou AD, Stergious GS, Vlachopoulos C, et al. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: Evidence for specific class-effects of antihypertensive drugs on pressure amplification. Curr Pharm Des 2009;15:272-89.
11. Koumaras C, Tzimous M, Stavrinou E, et al. Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics. Am J Cardiovasc Drugs 2012;12:143-56.
12. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
13. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
14. Spanos G, Kalaitzidis R, Karasavvidou D, et al. Efficacy of aliskiren and valsartan in hypertensive patients with albuminuria: a randomized parallel-group study. J Renin Angiotensin Aldosterone Syst 2013;14:315-21.
15. Frimodt-Møller M, Kamper AL, Strandgaard S, et al. Beneficial effects on arterial stiffness and pulse-wave reflection of combined enalapril and candesartan in chronic kidney disease-a randomized trial. PLoS One 2012;7:e41757.
16. Nedogoda SV, Ledyaeva AA, Chumachok EV, et al. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig 2013;33:553-61.
17. Peters CD, Kjaergaard KD, Jensen JD, et al. No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients. Kidney Int 2014;86:625-37.
18. Mitsuhashi H, Tamura K, Yamauchi J, et al. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis 2009;207:186-90.
19. Miyashita Y, Miyashita Y, Saiki A, et al. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. J Atheroscler Thromb 2009;16:621-6.
20. Shigenaga A, Tamura K, Dejima T, et al. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis. Nephron Clin Pract 2009;112:c31-40.
21. Rajagopalan S, Kariisa M, Dellegrottaglie S, et al. Angiotensin receptor blockade improves vascular compliance in healthy normotensive elderly individuals: results from a randomized double-blind placebo-controlled trial. J Clin Hypertens (Greenwich) 2006;8:783-90.
22. Eguchi K, Hoshide S, Ishikawa S, et al. Aggressive blood pressure-lowering therapy guided by home blood pressure monitoring improves target organ damage in hypertensive patients with type 2 diabetes/prediabetes. J Clin Hypertens (Greenwich) 2012;14:422-8.
23. Agata J, Nagahara D, Kinoshita S, et al. Angiotensin II receptor blocker prevents increased arterial stiffness in patients with essential hypertension. Circ J 2004;68:1194-8.
24. Rehman A, Rahman AR, Rasool AH. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors. J Hum Hypertens 2002;16:261-6.
25. Jekell A, Malmqvist K, Wallén NH, et al. Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: results from the SILVHIA study. J Cardiovasc Pharmacol 2013;62:559-66.
26. Park JB, Intengan HD, Schiffrin EL. Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension. J Renin Angiotensin Aldosterone Syst 2000;1:40-5.
27. Schneider MP, Delles C, Klingbeil AU, et al. Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial. J Renin Angiotensin Aldosterone Syst 2008;9:49-56.
28. Pozzobon CR, Gismondi RA, Bedirian R, et al. Functional Vascular Study in Hypertensive Subjects with Type 2 Diabetes Using Losartan or Amlodipine. Arq Bras Cardiol 2014;103:51-9.
29. Munakata M, Nagasaki A, Nunokawa T, et al. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Am J Hypertens 2004;17:1050-5.
30. Morimoto S, Yano Y, Maki K, et al. Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 2006;29:567-72.
31. Kosch M, Levers A, Lang D, et al. A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension. Nephrol Dial Transplant 2008;23:2280-5.
32. Klingbeil AU, John S, Schneider MP, et al. AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. J Hypertens 2002;20:2423-8.
33. Kim EJ, Song WH, Lee JU, et al. Efficacy of losartan and carvedilol on central hemodynamics in hypertensives: a prospective, randomized, open, blinded end point, multicenter study. Hypertens Res 2014;37:50-6.
34. Hayoz D, Zappe DH, Meyer MA, et al. Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen. J Clin Hypertens (Greenwich) 2012;14:773-8.
35. Levy BI, Michel JB, Salzmann JL, et al. Remodeling of heart and arteries by chronic converting enzyme inhibition in spontaneously hypertensive rats. Am J Hypertens 1991;4:240S-5S.
36. Isobe N, Taniguchi K, Oshima S, et al. Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. Circ J 2002;66:993-9.
37. Barra JG, Levenson J, Armentano RL, et al. In vivo angiotensin II receptor blockade and converting enzyme inhibition on canine aortic viscoelasticity. Am J Physiol 1997;272:H859-68.
38. Sharma AM, Janke J, Gorzelniak K, et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002;40:609-11.
39. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-9.
40. Togashi N, Ura N, Higashiura K, et al. The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. J Hypertens 2000;18:1605-10.